Drug Trial Radar · NCT07400003
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
519
Planned (sponsor's estimate)
Start
Jan 6, 2026
Primary completion
May 31, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.
Conditions
- Herpes Zoster
- mRNA Vaccine
Interventions
Low-dose experimental vaccineBiological
Lyophilized herpes zoster virus mRNA vaccine
High-dose experimental vaccineBiological
Lyophilized herpes zoster virus mRNA vaccine
Active-controlled vaccine ABiological
herpes zoster attenuated live vaccine, lyophilized
Active-controlled vaccine BBiological
Shingrix®
Placebo groupOther
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of adverse reactions within 30 daysTime frame: 0~30 days after each dose vaccination
- Seroconversion rate of gE antibodyTime frame: Day 30 after two doses
- Geometric mean concentration (GMC) of gE antibodyTime frame: Day 30 after two doses
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
Xinjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.